Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Rxi Pharmaceuticals Corp (NASDAQ:RXII)

0.30
Delayed Data
As of Feb 08
 +0.0104 / +3.59%
Today’s Change
0.27
Today|||52-Week Range
1.73
-21.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$18.9M

Company Description

RXi Pharmaceuticals Corp. is a biotechnology company. It focuses on discovering, developing and commercializing innovative therapies based on its proprietary, new-generation RNA interference platform. The company's proprietary therapeutic platform is comprised of novel RNAi compounds include rxRNAori and sd-rxRNA. Its clinical product candidate is RXI-109 a self-delivering RNAi compound developed for the reduction of dermal scarring in planned surgeries. RXI-109 is designed to reduce the expression of connective tissue growth factor a critical regulator of several biological pathways involved in scarring and fibrotic diseases. RXi Pharmaceuticals was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Contact Information

RXi Pharmaceuticals Corp.
257 Simarano Drive
Marlborough Massachusetts 01752
P:(508) 767-3861
Investor Relations:
(508) 929-3646

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Geert CauwenberghPresident, CEO, CFO & Director
Karen BulockVice President-Research
Lyn LibertineVice President-Medical Affairs & Safety Assessment
Pamela A. PavcoChief Development Officer
Caitlin KontulisSecretary & Controller